Bionics

New Pilot Study Using the FDA-Cleared Cionic Neural Sleeve Demonstrates Significant Improvements to Gait Impairments for Patients with Multiple Sclerosis

Retrieved on: 
星期二, 五月 28, 2024
Apps, Applications, Technology, Mobile, Wireless, Medical Devices, FDA, Health Technology, Software, Health, Data Management, CMSC, Doctor of Philosophy, Ankle, Foot, Bionics, Outline of health sciences, Movement, Canadian International Council, Cleveland State University, Neurotechnology, Walking, Pharmaceutical industry

CIONIC , the neurotech inventor pioneering bionic clothing, today announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking due to multiple sclerosis (MS).

Key Points: 
  • CIONIC , the neurotech inventor pioneering bionic clothing, today announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking due to multiple sclerosis (MS).
  • The real-world study, “Impact of the Cionic Neural Sleeve on Ankle Kinematics during Gait in Multiple Sclerosis,” evaluated the impact of CIONIC’s proprietary array-based stimulation approach to address neuromuscular walking challenges associated with foot drop, one of the most common gait impairments for individuals with neurologic conditions.
  • Results of the study demonstrated significant improvements for both measures, and all participants experienced improvements to dorsiflexion at heel strike and reductions in inversion during swing when functional electrical stimulation from the Cionic Neural Sleeve activated the affected muscles.
  • “These results show the tremendous power of our software-steered neuromodulation array and real-time adaptive algorithms to improve walking for individuals with MS.”
    To learn more about the Cionic Neural Sleeve, visit cionic.com .

Sonova announces Management Board succession

Retrieved on: 
星期五, 五月 10, 2024
Immersion, Consumer, Lilika, Bionics, LivaNova, Johnson & Johnson, GVP, Knowledge

Stäfa (Switzerland), May 7, 2024 – Sonova Holding AG, a leading provider of hearing care solutions, today announces upcoming appointments to its Management Board.

Key Points: 
  • Stäfa (Switzerland), May 7, 2024 – Sonova Holding AG, a leading provider of hearing care solutions, today announces upcoming appointments to its Management Board.
  • They have built strong teams and created good foundations for their successors and Sonova.
  • They have also demonstrated their leadership capabilities in various senior positions across different regions and businesses at Sonova.
  • Arnd comments: “We are excited that these three experienced leaders join our Management Board.

CIONIC Unveils New Offerings to Address Full Spectrum of Mobility Challenges with New Activities of Daily Living Exercise Regimen and Training Reports for Patients with Disabilities

Retrieved on: 
星期四, 五月 9, 2024
FDA, Health Technology, Retail, Data Management, Technology, Apps, Applications, General Health, Women, Medical Devices, Discount, Variety, Men, Family, Software, Consumer, Health, Mobile, Wireless, Leg, Hope, Safety, Disability, Bionics, Smartphone, Stroke, Wearable, Therapy, Patient, Movement, Thomas Edison, Gold, Nervous system, Multiple sclerosis, Multimedia, Marketing, Tetraplegia, Walking

The durable leg sleeve is transforming how device-based therapeutics are assisting patients with multiple sclerosis, strokes, spinal cord injuries, and other upper motor neuron diagnoses.

Key Points: 
  • The durable leg sleeve is transforming how device-based therapeutics are assisting patients with multiple sclerosis, strokes, spinal cord injuries, and other upper motor neuron diagnoses.
  • View the full release here: https://www.businesswire.com/news/home/20240509998099/en/
    The FDA-Cleared Cionic Neural Sleeve (Photo: Business Wire)
    “At CIONIC, we are obsessed with improving function for the millions living with impaired mobility.
  • We continually evaluate our offering and incorporate customer feedback to introduce meaningful changes through software updates,” said Jeremiah Robison, CIONIC Founder and CEO.
  • "By providing a wider variety of functional movement training and detailed progress reports, we're empowering our users with more tools to increase their functional mobility and independence."

Bionic Devices Market, Size, Global Forecast 2024-2030: Demand Grows for Rehabilitation and Functional Recovery Solutions - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 9, 2024
Technology, Health, Robotics, Medical Devices, Lead, Hospital, College of Engineering (KNUST), Disability, Prevalence, Prognosis, Bionics, Heart transplantation, Death, Diabetes, Rehabilitation, Gross domestic product, Entrepreneurship, Empowerment, Communication, Research, Mechanical, Life, Human, Electronics, Incidence, Patient, Consciousness, Crash, Quality of life, Accident, Medical device

The demand for bionic devices has surged in modern times because of their transformative effect on the quality of existence.

Key Points: 
  • The demand for bionic devices has surged in modern times because of their transformative effect on the quality of existence.
  • Technological improvements and extensive research and improvement efforts are critical drivers for expanding the development of the global bionic devices market.
  • This developing emphasis on rehabilitation and functional healing is vital to adopting and utilizing bionic devices.
  • These establishments function as hubs for prognosis, treatment, and rehabilitation, propelling the demand for bionic devices throughout numerous scientific specialties.

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Retrieved on: 
星期一, 五月 6, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Health Technology, Multimedia, License, Partnership, Glucagon, Insulin, Bionics, Pharmaceutical industry

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.
  • View the full release here: https://www.businesswire.com/news/home/20240506079856/en/
    “We’re excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes,” said Paul R. Edick, Chairman and CEO of Xeris.
  • “We will move quickly to support Beta Bionics in this important development program.”
    “If insulin is like the gas pedal in your car, then glucagon is the brakes,” said Sean Saint, CEO of Beta Bionics.
  • “Beta Bionics has always felt that a bi-hormonal glucose control system has real advantages over insulin alone…just like the brakes in your car.

TIME Reveals the Inaugural TIME100 Health List of the World's Most Influential People in Health

Retrieved on: 
星期四, 五月 2, 2024
Cancer, EVP, CDC, Bionics, Eli Lilly, Medicaid, Migrant Clinicians Network, Podcast, TIME, Future, Novo Nordisk, HEALTH, Medicare, Eli Lilly and Company, Apple, Letter, AstraZeneca, Woman, Northwell Health

--See the complete 2024 TIME100 Health list: time.com/time100health --See the TIME100 Health cover featuring an illustration by Peter Greenwood for TIME: https://bit.ly/3Uojcso 

Key Points: 
  • NEW YORK, May 2, 2024 /PRNewswire/ -- Today, TIME reveals the inaugural TIME100 Health list recognizing the 100 most influential individuals in health.
  • Health innovation, like this list, reflects humanity at its best: people using all their resourcefulness and ingenuity to help one another live better….
  • The youngest individual recognized on the inaugural TIME100 Health list is 28-year-old Dale Whelehan, CEO of Four Day Week Global.
  • See the full 2024 TIME100 Health list here: time.com/time100health
    TIME will convene the TIME100 Impact Dinner: Leaders Shaping the Future of Health to spotlight an array of leaders including those featured on the new TIME100 Health list of 100 individuals on May 13th in New York City.

Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal

Retrieved on: 
星期五, 四月 12, 2024
SCI, CMS, Bionics, Data analysis, Rehabilitation, DPT, Ekso Bionics, Life, Patient, Mental health, Medicare, Tetraplegia, Quality of life, Division, NCS, SAN, Health insurance

As previously announced, CMS approved use of Healthcare Common Procedure Coding System Code K1007 to bill Medicare for the Ekso Indego Personal.

Key Points: 
  • As previously announced, CMS approved use of Healthcare Common Procedure Coding System Code K1007 to bill Medicare for the Ekso Indego Personal.
  • This code can also be used by other public health insurance programs as well as private payers.
  • Ekso Bionics will work with inpatient and outpatient clinics across the country to qualify individuals with spinal cord injuries who can potentially benefit from the Ekso Indego Personal.
  • Ekso Bionics has worked with many of these facilities by offering clinical demonstrations, where interested individuals can trial the Ekso Indego Personal.

Global Bionic Devices Research Report 2024: Market to Surpass $10.25+ Billion by 2030, Driven by Transformative Impact on Quality of Life in Retaining Mobility and Independence - ResearchAndMarkets.com

Retrieved on: 
星期一, 四月 29, 2024
General Health, Health, Medical Devices, Conditional sentence, Amputation, WHO, Person, Huber loss, Hearing loss, Disability, Hospital, Bionics, Cardiology, Elective surgery, Growth, Environment, Incidence, Neurology, Disability studies, Consciousness, Dental implant, Crash, Rehabilitation, Ageing, Fixation, Quality of life, Accident, Prevalence, Medical device

The demand for bionic devices has surged in recent times because of their transformative effect on the quality of existence.

Key Points: 
  • The demand for bionic devices has surged in recent times because of their transformative effect on the quality of existence.
  • North America dominated the global bionic devices market in 2023 and is anticipated to lead the market throughout the forecast period.
  • The electronic bionic devices captured a significant share of the global bionic devices market in 2023.
  • It is predicted that the ambulatory surgical centers will capture nearly a quarter share of the total bionic devices market.

BOW unveils first-of-its-kind robotics software with global OEMs at Hannover Messe

Retrieved on: 
星期一, 四月 22, 2024
Software, Technology, Robotics, Language, BOW, Mac, Bionics, JavaScript, Machine learning, SDK, OEM, Research, OS, Python, NET, Multimedia, Running, Linux, InMotion, 3D printing

BOW , the universal robotics software company that makes programming robots code-agnostic, interoperable and scalable, will today demonstrate real-world applications at the Hannover Messe exhibition with partners Sarcomere Dynamics and inMotion robotic, Hall 5/D46-3.

Key Points: 
  • BOW , the universal robotics software company that makes programming robots code-agnostic, interoperable and scalable, will today demonstrate real-world applications at the Hannover Messe exhibition with partners Sarcomere Dynamics and inMotion robotic, Hall 5/D46-3.
  • Hannover Messe (22-26 April) is one of the world’s largest and most important events for Industrial Transformation, attracting over 130,000 attendees.
  • BOW is the official software partner for Sarcomere Dynamics and inMotion robotic - together with its partner Deep Robotics - two leading robotics companies that will be demonstrating BOW-enabled applications on their stands at Hannover Messe.
  • inMotion robotic and its partner Deep Robotics are a global OEM pioneering the development and industrial application of bionic quadruped robots.

Trella Health Enhances Marketscape Insights for HME and Infusion Organizations with the Addition of Claim and Patient Counts

Retrieved on: 
星期四, 四月 25, 2024
HME, Organization, Bionics, Commercial, Research, Marketing, Knowledge, Patient, GM, Infusion, Medicare, Growth, Medical device

ATLANTA, April 25, 2024 /PRNewswire/ -- Trella Health, the leader in HME and Infusion growth and productivity solutions, announces the recent release of claim and patient counts within its Marketscape Insights platform.

Key Points: 
  • HME and Infusion organizations can maximize growth potential and strategically target top referral sources by leveraging patient and claim counts.
  • ATLANTA, April 25, 2024 /PRNewswire/ -- Trella Health, the leader in HME and Infusion growth and productivity solutions, announces the recent release of claim and patient counts within its Marketscape Insights platform.
  • This highly requested insights feature provides HME and Infusion organizations with greater visibility into their market.
  • We are thrilled to have released visibility into Physician and Organization patient and claim counts within the Marketscape Insights for HME and Infusion platform.